Search clinical trials for: BioChaperone human insulin

Total 6244 results

HaEmek Medical Center, Israel

Completed

Basal Bolus vs. Sliding Scale for Treatment of Diabetic Patients in Medical Wards

Diabetes Mellitus Type 2
Novo Nordisk A/S

Completed

A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4) (ONWARDS 4)

Diabetes Mellitus, Type 2

United States, Mexico, Netherlands, Russian Federation, India, Belgium, Japan, Romania, Italy
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacodynamic Properties of NN5401 in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Mannkind Corporation

Terminated

Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks

Diabetes, Type 1

United States, Brazil
Norwegian University of Science and Technology

Completed

Treatment of Latent Autoimmune Diabetes of the Adult (LADA)

Diabetes

Norway
IRCCS San Raffaele

Terminated

Normalization of Fasting Glucose and the Incidence of Restenosis After Peripheral Angioplasty (LIMBISCH)

Type 2 Diabetes Mellitus | Peripheral Vascular Disease

Italy
University of Versailles
Assistance Publique - Hôpitaux de Paris

Completed

Combination of Corticotherapy and Intensive Insulin Therapy for Septic Shock (COIITSS)

Septic Shock

France
Novo Nordisk A/S

Completed

Safety of Insulin Detemir Produced by a New Process as Measured by Antibody Formation in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany, South Africa, Russian Federation, Former Serbia and Montenegro, North Macedonia
Novo Nordisk A/S

Completed

A Research Study of How Different Amounts of a New Medicine NNC0148-0287 C (Insulin 287) Works on the Blood Sugar of People Who Are Japanese With Type 1 Diabetes When Given Once a Week

Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

Comparison of Insulin Detemir Given Once or Twice Daily in Type 1 Diabetes (ADAPT)

Diabetes | Diabetes Mellitus, Type 1

France, Belgium, Luxembourg
Novo Nordisk A/S

Completed

Safety Follow-up on Children and Adolescents With Type 1 Diabetes Treated With Insulin Detemir. An Extension to Trial NN304-1689

Diabetes | Diabetes Mellitus, Type 1

France, Denmark, Finland, Russian Federation, Macedonia, The Former Yugoslav Republic of, Hungary, Bulgaria, United Kingdom, Turkey, Czech Republic, Poland
Sanofi

Terminated

Insulin Glargine for Diabetes Metabolism(DM)Type II Patients Under Enteral Nutrition

Diabetes Mellitus, Type 2

Brazil
Sanofi

Completed

Insulin Glulisine Administered Pre-meal Versus Post-meal in Adult Subjects With Type 2 Diabetes Mellitus Receiving Insulin Glargine as Basal Insulin

Diabetes Mellitus, Type 2

United States
Sanofi

Completed

Gulf, Lantus, Apidra Evaluation in Type 1 Diabetics Study (GLANS)

Diabetes Mellitus, Type 1

Bahrain, Kuwait, Qatar, United Arab Emirates
Sanofi

Completed

Insulin Glulisine, Insulin Lispro and Insulin Glargine in Type 1 or 2 Diabetes Mellitus

Diabetes Mellitus

China
Diasome Pharmaceuticals

Completed

Comparison of Different Insulin Dosing Algorithms Using Hepatic Directed Vesicle-Insulin Lispro and Insulin Degludec

Diabetes Mellitus, Type 1

United States
Novo Nordisk A/S

Completed

Investigating the Postprandial Glucose Metabolism After Treatment With Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Austria
Novo Nordisk A/S

Completed

A Randomised Trial Evaluating Continuous Subcutaneous Infusion of Formulations of NN1218 and NovoLog® in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

United States
Novo Nordisk A/S

Completed

A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 5)

Diabetes Mellitus, Type 2

United States, Poland, Puerto Rico, Canada, Hungary, Germany, Turkey, Greece
University of Minnesota

Completed

The Impact of Insulin Therapy on Protein Turnover in Pre-Diabetic Cystic Fibrosis Patients

Cystic Fibrosis

United States
Sanofi

Completed

Effect of Insulin Glulisine Compared to Insulin Aspart and Insulin Lispro When Administered by Continuous Subcutaneous Insulin Infusion (CSII) on Specific Pump Parameters in Patient With Type 1 Diabetes Mellitus (PUMP)

Diabetes Mellitus, Type 1

France, Australia, Spain, Sweden, United States, Austria, Hungary, Israel, Italy, United Kingdom, Korea, Republic of, Netherlands
AstraZeneca

Completed

A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

United States
Novo Nordisk A/S

Completed

Bioequivalence of Two NovoLog® Formulations in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

United States
Medical University of Graz
European Commission

Completed

Investigation of the Impact of Different Application Volumes of Insulin Aspart in Subjects With Type 1 Diabetes

Type 1 Diabetes

Austria
LI ZHAO

Completed

Acute Effects of rhBNP in Patients With PH Associated With Acute Exacerbation of Chronic Pulmonary Disease

Pulmonary Hypertension

China
Sanofi

Completed

Insulin Glulisine in Diabetes Mellitus, Type 2 (GINGER)

Diabetes Mellitus, Type 2

France, Spain, Italy, Belgium, Germany, Poland, Portugal, Czech Republic, Slovakia, Australia, Netherlands, Sweden, United Kingdom, Switzerland, Romania
Medical University of Warsaw

Completed

Normal Versus Dual Wave Insulin Bolus for High-protein Food

Type 1 Diabetes

Poland
Eli Lilly and Company

Completed

A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections (QWINT-4)

Type 2 Diabetes | Type 2 Diabetes Treated With Insulin

United States, Germany, Mexico, Argentina, Puerto Rico, Italy, Spain, India
Mountain Diabetes and Endocrine Center

Unknown

The Efficacy and Safety of Faster Insulin Aspart (Fiasp®) Compared to Conventional Insulin Aspart (NovoLog®) as Correction Bolus (PLATEAU)

Type 1 Diabetes Mellitus

United States
Wake Forest University Health Sciences
National Institute on Aging (NIA); General Electric

Completed

Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin Aspart (SNIFF-Quick)

Mild Cognitive Impairment | Alzheimer's Disease

United States
Nordsjaellands Hospital
Odense University Hospital; Zealand University Hospital; Aarhus University Hospital and other collaborators

Completed

Insulin Degludec and Symptomatic Nocturnal Hypoglycaemia (HypoDeg)

Type 1 Diabetes Mellitus | Nocturnal Hypoglycemia | Recurrent Severe Hypoglycaemia

Denmark
University of Palermo

Completed

Dulaglutide in Diabetic Patients, Relationship Between Arterial Stiffness, Endothelial Function, Clinical and Laboratory Variables

Diabetes Mellitus

Italy
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacodynamic Response of Faster Acting Insulin Aspart in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Efficacy and Safety of Levemir® Used as Basal Insulin

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Slovakia
Novo Nordisk A/S

Completed

Comparison of Insulin Glargine Against Insulin Aspart Infused Under the Skin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Delivery Systems

Denmark
Joslin Diabetes Center
Novo Nordisk A/S

Terminated

Glycemic Stability of Insulin Aspart Versus Insulin Lispro in Insulin Pump Therapy

Type 1 Diabetes Mellitus

United States
Novo Nordisk A/S

Completed

A Two Part Trial Investigating NN1952 in Healthy Subjects and Subjects With Type 1 and Type 2 Diabetes

Healthy | Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Germany
Sanofi

Completed

Insulins Glargine and gluLisine strAtegy Versus Premixed Insulin strAteGy: a cOmparative Study (GALAPAGOS)

Diabetes Mellitus, Type 2

Austria, United Arab Emirates, Spain, Romania, Colombia, Korea, Republic of, Brazil, Greece, Italy, China, Denmark, India, Kuwait, Mexico, Taiwan, Turkey
Sanofi

Completed

Intensive Insulin Glulisine Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin and Oral Glucose-lowering Drugs (CHANGING)

Diabetes Mellitus, Type 2

Algeria, Brazil, Israel, Lebanon, Mexico, Morocco, Peru, Saudi Arabia, United Arab Emirates, Venezuela
Sanofi

Completed

Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine (GEMELLI X)

Type 1 Diabetes Mellitus

United States
Inova Health Care Services

Withdrawn

The Inova Type 2 Diabetes Mellitus Study (InovaDM2)

Diabetes, Type 2

United States
AstraZeneca
Eli Lilly and Company

Completed

Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin

Diabetes Mellitus, Type 2

Taiwan, United Kingdom, Portugal, Spain, Netherlands, Croatia, Slovenia, Greece, Italy, Germany, Romania, Russian Federation
Rush University Medical Center
Novo Nordisk A/S

Completed

Management of Diabetes in the Emergency Room: a Randomized Trial of an Insulin Protocol.

Type 2 Diabetes Mellitus

United States
Novo Nordisk A/S

Completed

A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine

Diabetes Mellitus, Type 2

United States, Italy, Canada, Germany, Czechia
Novo Nordisk A/S

Completed

Within-subject Variability of Insulin Detemir in Children and Adolescents With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Comparison of Insulin Detemir or Insulin Glargine as Add on to Oral Antidiabetic Drugs in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, Germany, United Kingdom, Austria, Belgium, France, Ireland
Novo Nordisk A/S

Completed

Efficacy and Safety of a Fixed or a Flexible Supplementary Insulin Therapy in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

An Observational Study of Insulin Aspart and, if Necessary, Insulin Levemir (FlexPen®) in the Evening or at Bedtime

Diabetes Mellitus, Type 2 | Diabetes

Germany
Sanofi

Completed

Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2)

Diabetes Mellitus

United States
Novo Nordisk A/S

Completed

A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6) (ONWARDS 6)

Diabetes Mellitus, Type 1

United States, India, Italy, Russian Federation, United Kingdom, Canada, Netherlands, Austria, Japan, Spain, Germany, Turkey

3

Subscribe